You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
Boehringer Ingelheim
Harvard Business School
Medtronic
Merck

Last Updated: September 24, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,238,657

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,238,657 protect, and when does it expire?

Patent 9,238,657 protects FETROJA and is included in one NDA.

This patent has forty patent family members in thirty-three countries.

Summary for Patent: 9,238,657
Title:Cephalosporin having catechol group
Abstract: The present disclosure describes Cephem compounds of the formula: ##STR00001## wherein, X is N, CH or C--Cl; T is S or the like; A and G are lower alkylene or the like; B is a single bond or the like; D is optionally present, and when present is, --NR.sup.7--, --CO--, --CO--NR.sup.7--, --NR.sup.7--CO--, --NR.sup.7--CO--NR.sup.7--, or the like; F is optionally present, and when present is or phenylene; R.sup.3 and R.sup.4 are --OR.sup.8; R.sup.5 and R.sup.6 each is independently hydrogen, halogen, nitrile, or --OR.sup.8; or an ester at the carboxyl at the 7-position side chain or at the 4-position, a compound protected at the amino on the ring in the 7-side chain, a pharmaceutically acceptable salt, or a solvate thereof, which have a wide antimicrobial spectrum and have potent antimicrobial activity against beta-lactamase producing Gram negative bacteria.
Inventor(s): Nishitani; Yasuhiro (Osaka, JP), Yamawaki; Kenji (Osaka, JP), Takeoka; Yusuke (Sapporo, JP), Sugimoto; Hideki (Osaka, JP), Hisakawa; Shinya (Osaka, JP), Aoki; Toshiaki (Osaka, JP)
Assignee: SHIONOGI & CO., LTD. (Osaka, JP)
Application Number:13/063,878
Patent Claim Types:
see list of patent claims
Use; Composition; Compound;

Drugs Protected by US Patent 9,238,657

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Shionogi Inc FETROJA cefiderocol sulfate tosylate POWDER;INTRAVENOUS 209445-001 Nov 14, 2019 RX Yes Yes   Start Trial   Start Trial Y Y METHOD OF TREATING BACTERIAL INFECTIONS   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,238,657

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2008-280828Oct 31, 2008
PCT Information
PCT FiledOctober 27, 2009PCT Application Number:PCT/JP2009/068400
PCT Publication Date:May 06, 2010PCT Publication Number: WO2010/050468

International Family Members for US Patent 9,238,657

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2009310959   Start Trial
Brazil PI0921701   Start Trial
Canada 2736953   Start Trial
Chile 2011000939   Start Trial
China 102203100   Start Trial
Colombia 6331443   Start Trial
Costa Rica 20110144   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Baxter
Boehringer Ingelheim
Dow
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.